Ilaria Colombo

Bellinzona, TI, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

Journal: Drugs

Published: April 16, 2026

Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial.

Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial.

Journal: Cancer chemotherapy and pharmacology

Published: April 08, 2026

Predictive biomarkers for immunotherapy response in endometrial cancer: current insights and future directions.

Predictive biomarkers for immunotherapy response in endometrial cancer: current insights and future directions.

Journal: Exploration of targeted anti-tumor therapy

Published: February 04, 2026

Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges.

Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges.

Journal: EClinicalMedicine

Published: December 23, 2025

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 28, 2025

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 25, 2025

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 10, 2025

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 10, 2025

Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long-Term Survival.

Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long-Term Survival.

Journal: Case reports in oncological medicine

Published: September 20, 2025

Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancer.

Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancer.

Journal: Frontiers in immunology

Published: August 11, 2025

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Journal: Frontiers in oncology

Published: June 16, 2025

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).

Journal: Clinical pharmacokinetics

Published: June 15, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026